Paper831730
Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo.
Johnson RK. Biochem Pharmacol, 1977. Cited by 72 papers, by iCite.
Cite this record
ConductScience Library. Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo. Papers, record 831730. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/831730
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Aspartic Acid | Major topic |
| Organophosphorus Compounds | Major topic |
| Uridine | Major topic |
| Animals | |
| Body Weight | |
| Carbamates | |
| Lung Neoplasms | |
| Male | |
| Mice | |
| Mice, Inbred Strains | |
| Neoplasms, Experimental | |
| Phosphonoacetic Acid |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 72 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7679843 | Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors. | Transplant Proc | 1993 | https://conductscience.org/library/papers/7679843 | PubMed |
| 6178524 | Uridine rescue from the lethal toxicity of 5-fluorouracil in mice. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/6178524 | PubMed |
| 3815730 | Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole. | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3815730 | PubMed |
| 3742709 | Comparison of the bioavailability of uridine in mice after either oral or parenteral administration. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3742709 | PubMed |
| 3581416 | Effect of deoxycytidine on the in vitro response of human leukemia cells to inhibitors of de novo pyrimidine biosynthesis. | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3581416 | PubMed |
| 3396149 | Uridine pharmacokinetics in cancer patients. | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/3396149 | PubMed |
| 2822596 | Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390). | Invest New Drugs | 1987 | https://conductscience.org/library/papers/2822596 | PubMed |
| 2040033 | A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma. | Cancer Chemother Pharmacol | 1991 | https://conductscience.org/library/papers/2040033 | PubMed |
| 1911182 | Nucleoside salvage and resistance to antimetabolite anticancer agents. | Br J Cancer | 1991 | https://conductscience.org/library/papers/1911182 | PubMed |
| 393427 | m-AMSA and PALA: two new agents in cancer chemotherapy. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/393427 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/831730
GET https://conductscience.org/api/papers/v1/831730/authors